HC Wainwright Predicts MeiraGTx's Q2 Earnings (NASDAQ:MGTX)

Key Points

• HC Wainwright raised its Q2 2026 earnings estimate for MeiraGTx to a loss of $0.50 per share from $0.60, while keeping a Buy rating on the stock.
• MeiraGTx’s most recent earnings report showed a loss of $0.57 per share, beating estimates, but revenue was only $0.29 million versus expectations of $17 million.
• The stock has seen mixed analyst sentiment, with a Moderate Buy consensus and average price target of $25.83; shares were trading around $9.89 and up 3% on Thursday.

MeiraGTx Holdings PLC (NASDAQ:MGTX - Free Report) - Investment analysts at HC Wainwright boosted their Q2 2026 earnings estimates for MeiraGTx in a research note issued on Tuesday, May 26th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($0.50) for the quarter, up from their prior estimate of ($0.60). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for MeiraGTx's current full-year earnings is ($1.63) per share. HC Wainwright also issued estimates for MeiraGTx's Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.46) EPS, FY2026 earnings at ($1.98) EPS, Q1 2027 earnings at ($0.48) EPS, Q2 2027 earnings at ($0.50) EPS, Q3 2027 earnings at ($0.52) EPS and FY2027 earnings at $0.67 EPS.

MeiraGTx (NASDAQ:MGTX - Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.57) earnings per share for the quarter, beating analysts' consensus estimates of ($0.61) by $0.04. The business had revenue of $0.29 million during the quarter, compared to the consensus estimate of $17.00 million. MeiraGTx had a negative net margin of 151.12% and a negative return on equity of 1,065.47%.

A number of other research analysts also recently commented on MGTX. Wall Street Zen raised shares of MeiraGTx from a "sell" rating to a "hold" rating in a research report on Sunday, April 5th. Piper Sandler lifted their price objective on shares of MeiraGTx from $26.00 to $30.00 and gave the company an "overweight" rating in a research report on Wednesday, April 22nd. Chardan Capital reissued a "buy" rating and issued a $35.00 price objective on shares of MeiraGTx in a research report on Friday, March 27th. Weiss Ratings reissued a "sell (d-)" rating on shares of MeiraGTx in a research report on Tuesday, April 21st. Finally, Bank of America lifted their price objective on shares of MeiraGTx from $14.00 to $16.00 and gave the company a "buy" rating in a research report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $25.83.

MeiraGTx Trading Up 3.0%

MeiraGTx stock opened at $9.89 on Thursday. The company has a market cap of $915.91 million, a P/E ratio of -6.68 and a beta of 1.23. MeiraGTx has a 1-year low of $5.02 and a 1-year high of $11.85. The company has a fifty day simple moving average of $9.19 and a 200 day simple moving average of $8.31.

Institutional Trading of MeiraGTx

Several hedge funds and other institutional investors have recently bought and sold shares of MGTX. AQR Capital Management LLC bought a new position in MeiraGTx in the 1st quarter valued at about $557,000. Rhumbline Advisers increased its holdings in MeiraGTx by 9.4% in the 2nd quarter. Rhumbline Advisers now owns 63,715 shares of the company's stock valued at $415,000 after buying an additional 5,488 shares during the period. Brown Advisory Inc. bought a new position in MeiraGTx in the 2nd quarter valued at about $326,000. Qube Research & Technologies Ltd bought a new position in MeiraGTx in the 2nd quarter valued at about $530,000. Finally, Quantinno Capital Management LP bought a new position in MeiraGTx in the 2nd quarter valued at about $319,000. Institutional investors and hedge funds own 67.48% of the company's stock.

Insiders Place Their Bets

In other MeiraGTx news, CEO Alexandria Forbes sold 62,000 shares of MeiraGTx stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $9.17, for a total value of $568,540.00. Following the completion of the sale, the chief executive officer owned 1,387,695 shares in the company, valued at $12,725,163.15. The trade was a 4.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Richard Giroux sold 56,000 shares of MeiraGTx stock in a transaction dated Tuesday, April 21st. The stock was sold at an average price of $10.22, for a total transaction of $572,320.00. Following the completion of the sale, the chief financial officer owned 971,530 shares of the company's stock, valued at $9,929,036.60. This trade represents a 5.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 207,661 shares of company stock worth $1,859,187 in the last quarter. 7.50% of the stock is currently owned by corporate insiders.

About MeiraGTx

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx's pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company's lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.